1,753
Views
27
CrossRef citations to date
0
Altmetric
Research Article

Chitosan/poly (lactic acid)-coated piceatannol nanoparticles exert an in vitro apoptosis activity on liver, lung and breast cancer cell lines

&
Pages 274-282 | Received 07 Sep 2017, Accepted 23 Dec 2017, Published online: 03 Jan 2018

Figures & data

Table 1. Determination of drug and polymers.

Figure 1. In vitro drug release of CS/PLA-PIC NPs formulations for 6 days.

Figure 1. In vitro drug release of CS/PLA-PIC NPs formulations for 6 days.

Figure 2. Antioxidants activity of CS-PLA NPs, PIC and CS/PLA-PIC NPs with the control of quercitin. (a) DPPH (b) SOD and (c) NO scavenging activities.

Figure 2. Antioxidants activity of CS-PLA NPs, PIC and CS/PLA-PIC NPs with the control of quercitin. (a) DPPH (b) SOD and (c) NO scavenging activities.

Figure 3. (A) MTT assay of CS-PLA NPs, PIC and CS/PLA-PIC NPs with (a) HepG2. (b) A549 (c) MCF7 cell lines. (B) LDH activity of CS-PLA NPs, PIC and CS/PLA-PIC NPs with (a) HepG2. (b) A549 (c) MCF7 cell lines.

Figure 3. (A) MTT assay of CS-PLA NPs, PIC and CS/PLA-PIC NPs with (a) HepG2. (b) A549 (c) MCF7 cell lines. (B) LDH activity of CS-PLA NPs, PIC and CS/PLA-PIC NPs with (a) HepG2. (b) A549 (c) MCF7 cell lines.

Figure 4. Analysis of DNA isolated from HepG2, A549 and MCF cells incubated with IC30 and IC50 concentration of CS/PLA-PIC NPs for 24 h; cells without treatment (lane C), HepG2 cells treated with 20 µg/ml (lane 1), and 40 µg/ml (lane2), A549 cells treated with 40 µg/ml (lane 1), and 60 µg/ml (lane 2) and MCF7 cells treated with 40 µg/ml(lane 1), and 60 µg/ml(lane 2).

Figure 4. Analysis of DNA isolated from HepG2, A549 and MCF cells incubated with IC30 and IC50 concentration of CS/PLA-PIC NPs for 24 h; cells without treatment (lane C), HepG2 cells treated with 20 µg/ml (lane 1), and 40 µg/ml (lane2), A549 cells treated with 40 µg/ml (lane 1), and 60 µg/ml (lane 2) and MCF7 cells treated with 40 µg/ml(lane 1), and 60 µg/ml(lane 2).

Figure 5. Cells stained with AO and EB of CS/PLA-PIC treated HepG2, A549, and MCF cells at 24 h. Cells without treatment (control) HepG2 cells treated with (a) 20 µg/ml, (b) 40 µg/ml and (c) 60 µg/ml. A549 cells treated with (a) 40 µg/ml, (b) 60 µg/ml and (c) 80 µg/ml. MCF7 cells treated with (a) 40 µg/ml, (b) 60 µg/ml and (c) 80 µg/ml.

Figure 5. Cells stained with AO and EB of CS/PLA-PIC treated HepG2, A549, and MCF cells at 24 h. Cells without treatment (control) HepG2 cells treated with (a) 20 µg/ml, (b) 40 µg/ml and (c) 60 µg/ml. A549 cells treated with (a) 40 µg/ml, (b) 60 µg/ml and (c) 80 µg/ml. MCF7 cells treated with (a) 40 µg/ml, (b) 60 µg/ml and (c) 80 µg/ml.

Figure 6. Flow Cytometric analysis of the cancer cell lines treated with CS/PLA-PIC NPs (right) compared with control (left).

Figure 6. Flow Cytometric analysis of the cancer cell lines treated with CS/PLA-PIC NPs (right) compared with control (left).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.